Home
>
US Stocks
>
PDS BIOTECHNOLOGY CORP

PDS BIOTECHNOLOGY CORP (PDSB)

$9.9

+0.32

(+3.34%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Performance

  • $9.15
    $10.27
    $9.90
    downward going graph

    7.57%

    Downside

    Day's Volatility :10.9%

    Upside

    3.6%

    downward going graph
  • $2.89
    $13.65
    $9.90
    downward going graph

    70.81%

    Downside

    52 Weeks Volatility :78.83%

    Upside

    27.47%

    downward going graph

Returns

PeriodPDS BIOTECHNOLOGY CORPSector (Health Care)Index (Russel 2000)
3 Months
23.45%
0.7%
-6.8%
6 Months
-2.04%
-8.3%
-6.0%
1 Year
158.22%
-1.9%
-4.6%
3 Years
685.25%
25.3%
25.9%

Highlights

Market Capitalization
261.1M
Book Value
$1.34
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.8
Wall Street Target Price
19.29
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-41.14%
Return On Equity TTM
-86.79%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-42.6M
Diluted Eps TTM
-1.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.47
EPS Estimate Next Year
-1.49
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for PDS BIOTECHNOLOGY CORP(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 94.85%

Current $9.90
Target $19.29

Technicals Summary

Sell

Neutral

Buy

PDS BIOTECHNOLOGY CORP is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
PDS BIOTECHNOLOGY CORP
PDS BIOTECHNOLOGY CORP
57.05%
-2.04%
158.22%
685.25%
957.4%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
PDS BIOTECHNOLOGY CORP
PDS BIOTECHNOLOGY CORP
NA
NA
NA
-1.47
-0.87
-0.41
0.0
1.34
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
PDS BIOTECHNOLOGY CORP
PDS BIOTECHNOLOGY CORP
Buy
$261.1M
957.4%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Vanguard Group Inc

    4.21%

  • Two Sigma Advisers, LLC

    1.90%

  • Two Sigma Investments LLC

    1.61%

  • BlackRock Inc

    1.47%

  • Millennium Management LLC

    1.46%

  • LPL Financial Corp

    1.23%

Corporate Announcements

  • PDS BIOTECHNOLOGY CORP Earnings

    PDS BIOTECHNOLOGY CORP’s price-to-earnings ratio stands at None

    Read More

Company Information

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Organization
PDS BIOTECHNOLOGY CORP
Employees
26
CEO
Dr. Frank K. Bedu-Addo Ph.D.
Industry
Biotechnology

Discover More

FAQs